Human monoclonal anti-amyloid-beta antibodies

Details Human monoclonal anti-amyloid-beta antibodies Human monoclonal anti-amyloid-beta antibodies

2011-05-10

2011-05-10

Kemmerer, Elizabeth C. (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S139100, C530S388150

Reexamination Certificate

active

07939075

ABSTRACT:
Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

REFERENCES:
patent: 6787139 (2004-09-01), Schenk
patent: 6787523 (2004-09-01), Schenk
patent: 6818218 (2004-11-01), Schenk
patent: 6866849 (2005-03-01), Schenk
patent: 6866850 (2005-03-01), Schenk
patent: 6962707 (2005-11-01), Schenk
patent: 6972127 (2005-12-01), Schenk
patent: 7195761 (2007-03-01), Holtzman et al.
patent: 2002/0009445 (2002-01-01), Du et al.
patent: 2002/0182660 (2002-12-01), Fong
patent: 2003/0059937 (2003-03-01), Ruben et al.
patent: 2003/0083277 (2003-05-01), Hersh
patent: 2004/0170626 (2004-09-01), Schuurman et al.
patent: 2005/0019330 (2005-01-01), Schenk
patent: 2005/0106626 (2005-05-01), Pieczenik
patent: 2006/0039906 (2006-02-01), Holtzman et al.
patent: 2006/0246071 (2006-11-01), Green et al.
patent: 0 440 619 (1996-01-01), None
patent: 1 172 378 (2002-01-01), None
patent: 1 308 461 (2003-05-01), None
patent: 1 666 061 (2006-06-01), None
patent: WO 94/17197 (1994-08-01), None
patent: WO 96/15452 (1996-05-01), None
patent: WO 98/44955 (1998-10-01), None
patent: WO 01/42306 (2001-06-01), None
patent: WO 02/074240 (2002-09-01), None
patent: WO 03/040183 (2003-05-01), None
patent: WO 03/051374 (2003-06-01), None
patent: WO 01/62801 (2003-08-01), None
patent: WO 03/070760 (2003-08-01), None
patent: WO 03/077858 (2003-09-01), None
patent: WO 2004/013172 (2004-02-01), None
patent: WO 2004/024090 (2004-03-01), None
patent: WO 2004/031400 (2004-04-01), None
patent: WO 2004/032868 (2004-04-01), None
patent: WO 2004/056318 (2004-07-01), None
patent: WO 2004/067561 (2004-08-01), None
patent: WO 2004/080419 (2004-09-01), None
patent: WO 2005/025516 (2005-03-01), None
patent: WO 2005/082939 (2005-09-01), None
patent: WO 2005/123775 (2005-12-01), None
patent: WO 2006/017173 (2006-02-01), None
patent: WO 2006/040153 (2006-04-01), None
patent: WO 2006/047254 (2006-05-01), None
patent: WO 2006/055178 (2006-05-01), None
patent: WO 2006/081171 (2006-08-01), None
patent: WO 2006/081587 (2006-08-01), None
patent: WO 2006/094724 (2006-09-01), None
patent: WO 2006/103116 (2006-10-01), None
patent: WO 2006/118959 (2006-11-01), None
patent: WO 2007/062088 (2007-05-01), None
patent: WO 2007/064972 (2007-06-01), None
patent: WO 2007/068412 (2007-06-01), None
patent: WO 2007/108756 (2007-09-01), None
Gaskin, et al., Human Antibodies Reactive with Beta-Amyloid Protein in Alzheimer's Disease, Journal of Experimental Medicine, Tokyo, Japan, 1993, vol. 177, No. 4, pp. 1181-1186.
International Search Report for PCT/IB2008/000456, mailed Feb. 12, 2009.
Bard et al.; “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease;” Nature Medicine; vol. 6, No. 8; Aug. 2000; pp. 916-919.
Bilkova et al.; “Epitope extraction technique using a proteolytic magnetic reactor combined with Fourier-transform ion cyclotron resonance mass spectrometry as a tool for the screening of potential vaccine lead peptides;” Eur. J. Mass Spectrom., vol. 11; 2005; pp. 489-495 (XP009084150).
Dodel et al.; “Human Antibodies against Amyloid β Peptide: A Potential Treatment for Alzheimer's Disease;” Annals of Nuerology; vol. 52, No. 2; Aug. 2002; pp. 253-256.
Dodel et al.; “Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease;” J. Neurol. Psychiatry; vol. 75; 2004; pp. 1472-1474.
Du et al.; “Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity;” Brain; vol. 126; Jun. 23, 2003; pp. 1935-1939.
Du et al.; “Reduced levels of amyloid β-peptide antibody in Alzheimer disease,” Neurology; vol. 57; 2001; pp, 801-805.
Gruden et al.; “Autoimmune Responses to Amyloid Structures of AB(25-35)Peptide and Human Lysozyme in the Serum of Patients with Progressive Alzheimer's Disease;” Dementia and Geriatric Cognitive Disorders; vol. 18; 2004; pp 165-171 (XP008056285).
Improta et al.; “Structure and Conformational Behavior of Biopolymers by Density Functional Calculations Employing Periodic Boundary Conditions. I. The Case of Polyglycine, Polyalanine, and Poly-α-aminoisobutyric Acid in Vacuo;” J. Am. Chem. Soc.; vol. 123; 2001; pp. 3311-3322 (XP-002434952).
Istrin et al. “Intravenous Immunoglobulin Enhances the Clearance of Fibrillar Amyloid-β Peptide,” Journal of Neuroscience Research; vol. 84; 2006; pp. 434-443.
Koo et al., “Amyloid β-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth,” Proc. Natl. Acad. Sci. USA; vol. 90; 1993; pp. 4748-4752 (XP-002434874).
Manea et al, “Synthesis, Solution Conformation, and Antibody Recognition of Oligotuftsin-Based Conjugates Containing a β-Amyloid (4-10) Plaque-Specific Epitope,” Bioconjugate Chem.; vol. 16; 2005; pp. 921-928 (XP-002434951).
Manea et al., “Polypeptide Conjugates Comprising a β-Amyloid Plaque-Specific Epitope as new Vaccine Structures Against Alzheimer's Disease,” Biopolymers (Peptide Science), vol. 76; 2004; pp. 503-511 (XP009043837).
Markaryan et al., “Atypical Processing of Amyloid Precursor Fusion Protein by Proteolytic Activity inPichia pastoris,” Biochemical and Biophysical Research Communications; vol. 262; 1999; pp. 263-268 (XP-002441209).
McLaurin et al., “Therapeutically effective antibodies against amyloid-β peptide target amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis,” Nature Medicine; vol. 8; No. 11; 2002; pp. 1263-1269.
McLean et al., “Amyloid A β levels in Alzheimer's disease—A diagnostic tool and the key to understanding the natural history of Aβ,” Journal of Alzheimer's Disease; vol. 3; 2001; pp. 305-312 (XP009084295).
Mezo et al., “Synthesis and Structural Characterization of Bioactive Peptide Conjugates using Thioether Linkage Approaches,” Journal of Peptide Science; vol. 10; 2004; pp. 701-713 (XP-002434950).
O'Nuallain et al., “Diagnostic of Therapeutic Potential of Amyloid-Reactive IgG Antibodies Contained in Human Sera,” The Journal of Immunology; vol. 176: 2006; pp. 7071-7078.
Piket et al., “Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro,” The Journal of Biological Chemistry; vol. 270; 1995; pp. 23895-23898 (XP-002444096).
Portelius et al., “An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid,” Neuroscience Letters; vol. 409; 2006; pp. 215-219 (XP-002434875).
Selkoe, Dennis J.; “Translating cell biology into therapeutic advances in Alzheimer's disease;” Nature; vol. 399, No. 6738; Jun. 24, 1999; pp. A23-A31.
Solomon, Beka; “Intravenous immunoglobulin and Alzheimer's disease immunotherapy,” Current Opinon in Molecular Therapeutics; vol. 9, No. 1; 2007; pp. 79-85.
Solomon, Beka; “Clinical immunologic approaches for the treatment of Alzheimer's disease,” Expert Opin. Investig. Drugs; vol. 16, No. 6; 2007; pp. 819-828.
Solomon, Beka; “Antibody-mediated immunotherapy for Alzheimer's disease,” Current Opinion in Investigational Drugs; vol. 8, No. 7; 2007; pp. 519-524.
Solomon, Beka; “Alzheimer's disease immunotherapy: From in

Affiliated with

Also associated with

Rating

Human monoclonal anti-amyloid-beta antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human monoclonal anti-amyloid-beta antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal anti-amyloid-beta antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2681764